Systemic Chemotherapy in Metastatic Castration-Resistant Prostate Cancer
Most chemotherapeutic agents available for prostate cancer have been used by single agents or various combinations. Historically, cyclophosphamide, 5-fluorouracil, estramustine, cisplatin, carboplatin, doxorubicin, mitoxantrone, paclitaxel, and docetaxel have been used . With the exception of docetaxel (and the related agent, cabazitaxel) and mitoxantrone, the other agents for cytotoxic chemotherapy are not being used anymore because these agents have not been proved with either symptomatic improvements or survival benefit. Clinical trials using chemotherapy regimens used since 2000 have shown that the survival benefit of metastatic castration-resistant prostate cancer (mCRPC) patients is between 16 and 20 months when used as a first-line chemotherapy [2, 3], but less than 6–12 months when using historical chemotherapy regimens before 2000s .
- 1.Eisenberger MA. Chemotherapy for prostate carcinoma. NCI Monogr. 1988;7:151–63.Google Scholar
- 4.Tannock IF, Osoba D, Stockler MR, Ernst DS, Neville AJ, Moore MJ, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol. 1996;14(6):1756–64.CrossRefPubMedGoogle Scholar
- 17.Sternberg CN, Petrylak DP, Sartor O, Witjes JA, Demkow T, Ferrero JM, et al. Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial. J Clin Oncol. 2009;27(32):5431–8.CrossRefPubMedGoogle Scholar
- 24.Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the prostate cancer clinical trials working group. J Clin Oncol. 2008;26(7):1148–59.CrossRefPubMedPubMedCentralGoogle Scholar